Immunomedics, Inc. Reports Multiple Objective Responses in Solid Cancers With IMMU-132

Published: Oct 23, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BOSTON, Oct. 22, 2013 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that its newest antibody-drug conjugate (ADC), IMMU-132, has produced durable partial responses in three different cancer types in early phase of clinical evaluation.

Help employers find you! Check out all the jobs and post your resume.

Back to news